基于2016年世界卫生组织中枢神经系统新分类的H3.3 K27M突变对IV级脊髓胶质瘤预后和生存的影响
本研究回顾单中心25例IV级脊髓胶质瘤手术患者,按2016年WHO分类分析预后因素。中位总生存37.1个月,无病生存18.5个月。仅K27M状态有显著预后价值,K27M突变阳性患者总生存(40.07个月)长于阴性患者(11.63个月,P<.0001)。
要点
- K27M突变阳性患者总生存40.07个月,阴性患者11.63个月,P<.0001。
- K27M突变阳性患者无病生存20.85个月,阴性患者8.72个月,P=.0241。
- K27M突变并非主要的不良预后因素,需进一步研究用于风险分层和治疗优化。
核心结论
- 本研究是采用新WHO分类的首个且最大宗的关于原发IV级脊髓胶质瘤预后的报告,揭示了H3.3 K27M突变并非主要的不良预后因素。
研究设计与样本
- 单中心选取25例接受手术的IV级脊髓胶质瘤患者,全部经2016年WHO中枢神经系统分类组织学确诊为胶质母细胞瘤或「伴H3 K27M突变的弥漫性中线胶质瘤」。
主要发现
- 平均年龄39.1岁,男女比例18:7。
- 肿瘤位于胸段脊髓53.3%、颈段脊髓40%、腰段6.7%。
- 中位总生存37.1个月,中位无病生存18.5个月。
- K27M突变阳性20例(80%),阳性患者总生存40.07个月长于阴性患者11.63个月(P<.0001),无病生存20.85个月长于阴性患者8.72个月(P=.0241)。
- 治疗方式无统计学差异。
局限性
- 需进一步研究探索K27M突变以用于风险分层和治疗优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spinal cord glioma grade IV is a rare, diffuse midline glioma. H3 K27M-mutant was classified in a different entity in the 2016 World Health Organization (WHO) classification recently. No reports about prognosis of spinal cord glioma grade IV are available yet. OBJECTIVE: To analyze the prognostic factors for spinal cord glioma grade IV. METHODS: Twenty-five patients with spinal cord glioma of grade IV who underwent surgery in a single institute were selected. All grade IV spinal cord glioma histologically confirmed as glioblastoma or "diffuse midline glioma with H3 K27M-mutant" by the 2016 WHO classification of the central nervous system were included. Basic demographics, treatment modalities, and pathological tumor molecular profiles were investigated for prognosis. RESULTS: Mean age was 39.1 yr; male to female ratio was 18 : 7. Tumor was located in thoracic cord (53.3%), cervical cord (40%), and lumbar area (6.7%). Median overall survival was 37.1 mo; median disease-free survival was 18.5 mo. Treatment modality showed no statistical difference. Only K27M profile showed significant prognostic value, 20 patients (80%) showed K27M mutation positive, K27M mutation patients showed longer overall survival (40.07 mo) than K27M negative patients (11.63 mo, P < .0001), and disease-free survival (20.85 vs 8.72 mo, P = .0241). CONCLUSION: This study is the first and largest report of the prognosis of primary spinal cord grade IV glioma using the new WHO classification. This study reported survival analysis and prognostic factors, and revealed that H3.3 K27M mutation is not a major poor prognostic factor. Further studies to explore K27M mutations needed for risk stratification and therapy optimization.
引用
- Yi S, Choi S, Shin DA, et al. Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System. Neurosurgery. 2019. PMID: 29718432. doi:10.1093/neuros/nyy150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。